National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Cancer Institute funds early phase clinical trials for cancer treatment and diagnosis, focusing on targeted interventions relevant to specific research programs.
Funder: National Institutes of Health
Due Dates: May 7, 2025 (AIDS) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | January 7, 2027 (AIDS)
Funding Amounts: Up to $499,999 direct costs per year, for a maximum project period of 5 years (R01 mechanism).
Summary: Supports investigator-initiated early phase (Phase 0, I, II) clinical trials of cancer-targeted diagnostic and therapeutic interventions relevant to NCI’s DCTD and OHAM research missions.
Key Information: Phase III trials are not supported; at least one clinical trial must be included per application; foreign and domestic applicants are eligible.
Description
This opportunity from the National Cancer Institute (NCI), part of the NIH, funds investigator-initiated early phase clinical trials (Phase 0, I, and II) focused on cancer treatment and diagnosis. Projects must implement at least one clinical trial of a cancer-targeted diagnostic or therapeutic intervention that aligns with the research missions of the Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM). The program is designed to support a broad range of early phase clinical trial types, including single-site, multi-site, mechanistic, feasibility, pragmatic, ancillary, pharmacodynamic, biomarker-driven, co-clinical, and HIV/AIDS-related trials.
Applications may propose a clinical trial as the sole research aim or in combination with other research objectives. The program does not support Phase III trials, observational studies that do not meet the NIH definition of a clinical trial, or behavioral interventions without a therapeutic endpoint.
